Zr-89-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up

F Bensch; AH Brouwers; MN Lub-de Hooge; JR Jong; B van der Vegt; Stefan Sleijfer; EGE de Vries; CP Schroder

doi:10.1007/s00259-018-4099-8

Zr-89-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up

F Bensch
, AH Brouwers
, MN Lub-de Hooge
, JR Jong
, B van der Vegt
, Stefan Sleijfer
, EGE de Vries
, CP Schroder

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

134 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	2300-2306
Number of pages	7
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	45
Issue number	13
DOIs	https://doi.org/10.1007/s00259-018-4099-8
Publication status	Published - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research programs

EMC MM-03-86-01

Access to Document

10.1007/s00259-018-4099-8

Cite this

Bensch, F., Brouwers, AH., Lub-de Hooge, MN., Jong, JR., van der Vegt, B., Sleijfer, S., de Vries, EGE., & Schroder, CP. (2018). Zr-89-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up. European Journal of Nuclear Medicine and Molecular Imaging, 45(13), 2300-2306. https://doi.org/10.1007/s00259-018-4099-8

@article{e6e8a9ee411c4e99b8299fbc58322e1c,

title = "Zr-89-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up",

author = "F Bensch and AH Brouwers and \{Lub-de Hooge\}, MN and JR Jong and \{van der Vegt\}, B and Stefan Sleijfer and \{de Vries\}, EGE and CP Schroder",

year = "2018",

doi = "10.1007/s00259-018-4099-8",

language = "Undefined/Unknown",

volume = "45",

pages = "2300--2306",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "Springer",

number = "13",

}

Bensch, F, Brouwers, AH, Lub-de Hooge, MN, Jong, JR, van der Vegt, B, Sleijfer, S, de Vries, EGE & Schroder, CP 2018, 'Zr-89-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up', European Journal of Nuclear Medicine and Molecular Imaging, vol. 45, no. 13, pp. 2300-2306. https://doi.org/10.1007/s00259-018-4099-8

Zr-89-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up. / Bensch, F; Brouwers, AH; Lub-de Hooge, MN et al.
In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 45, No. 13, 2018, p. 2300-2306.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Zr-89-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up

AU - Bensch, F

AU - Brouwers, AH

AU - Lub-de Hooge, MN

AU - Jong, JR

AU - van der Vegt, B

AU - Sleijfer, Stefan

AU - de Vries, EGE

AU - Schroder, CP

PY - 2018

Y1 - 2018

U2 - 10.1007/s00259-018-4099-8

DO - 10.1007/s00259-018-4099-8

M3 - Article

C2 - 30058029

SN - 1619-7070

VL - 45

SP - 2300

EP - 2306

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

IS - 13

ER -